

Effects of preservative-free tafluprost on tear film osmolarity and
intraocular pressure in previously treated patients with

Clinical Ophthalmology

6, 103

DOI: [10.2147/oph.s28104](https://doi.org/10.2147/oph.s28104)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Tafluprost in the treatment of glaucoma. Expert Review of Ophthalmology, 2012, 7, 401-407.	0.6	1
2	Tafluprost: The First Preservative-Free Prostaglandin to Treat Open-Angle Glaucoma and Ocular Hypertension. Annals of Pharmacotherapy, 2012, 46, 1506-1510.	1.9	27
3	Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma. Clinical Ophthalmology, 2012, 7, 7.	1.8	8
4	TearLab [®] Osmolarity System for diagnosing dry eye. Expert Review of Molecular Diagnostics, 2013, 13, 119-129.	3.1	49
5	Aclaramiento lagrimal y sintomatología ocular en pacientes tratados con prostaglandinas sin conservantes. Archivos De La Sociedad Espanola De Oftalmología, 2013, 88, 88-91.	0.2	5
6	Tear clearance and ocular symptoms in patients treated with preservative-free prostaglandins. Archivos De La Sociedad Espanola De Oftalmología, 2013, 88, 88-91.	0.2	4
7	Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity. Eye, 2013, 27, 1142-1150.	2.1	50
8	Glaucoma therapy and ocular surface disease. Current Opinion in Ophthalmology, 2013, 24, 136-143.	2.9	85
9	Benzalkonium Chloride-Induced Denervation of Orbicularis Oculi Muscle in Rabbits. , 2013, 54, 1868.		1
10	Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. British Journal of Ophthalmology, 2013, 97, 1510-1515.	3.9	60
11	Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension. Clinical Ophthalmology, 2013, 7, 901.	1.8	12
12	Glaucoma management: relative value and place in therapy of available drug treatments. Therapeutic Advances in Chronic Disease, 2014, 5, 30-43.	2.5	62
13	Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opinion on Pharmacotherapy, 2014, 15, 1737-1747.	1.8	85
14	Comparison of Corneal Safety and Intraocular Pressure-Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 340-345.	1.4	8
15	Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension. Advances in Therapy, 2014, 31, 1213-1227.	2.9	35
16	Additive Effect of Preservative-free Sodium Hyaluronate 0.1% in Treatment of Dry Eye Syndrome With Diquafosol 3% Eye Drops. Cornea, 2014, 33, 935-941.	1.7	38
17	Benzalkonium Chloride and Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 163-169.	1.4	68
18	Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients With Existing Superficial Punctate Keratitis. Journal of Glaucoma, 2015, 24, e145-e150.	1.6	13

#	ARTICLE	IF	CITATIONS
19	Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study. Canadian Journal of Ophthalmology, 2015, 50, 132-136.	0.7	29
20	Effect of Glaucoma Medication in Tear Film Osmolarity of Patients Without Symptoms of Ocular Discomfort. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 330-334.	1.4	3
21	Mechanisms of benzalkonium chloride toxicity in a human trabecular meshwork cell line and the protective role of preservative-free tafluprost. Clinical and Experimental Ophthalmology, 2015, 43, 164-172.	2.6	22
22	Quality of Life in Glaucoma: A Review of the Literature. Advances in Therapy, 2016, 33, 959-981.	2.9	167
23	Hyperosmolarity and Benzalkonium Chloride Differently Stimulate Inflammatory Markers in Conjunctiva-Derived Epithelial Cells in vitro. Ophthalmic Research, 2017, 58, 40-48.	1.9	27
24	Tear fluid-eye drops compatibility assessment using surface tension. Drug Development and Industrial Pharmacy, 2017, 43, 275-282.	2.0	28
25	Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study. BMC Ophthalmology, 2017, 17, 136.	1.4	20
26	Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. Drugs, 2018, 78, 39-64.	10.9	43
27	Management of Glaucoma in Patients with Ocular Surface Disease. , 2018, , 125-138.		0
28	Preservatives in glaucoma medication. British Journal of Ophthalmology, 2018, 102, 1497-1503.	3.9	83
29	Ocular Surface Disease in the Glaucoma Patient. International Ophthalmology Clinics, 2018, 58, 23-33.	0.7	6
30	<p></p>The use of preservatives in dry eye drops</p>. Clinical Ophthalmology, 2019, Volume 13, 1409-1425.	1.8	58
31	Chloramphenicol/sulfobutyl ether-β-cyclodextrin complexes in an ophthalmic delivery system: prolonged residence time and enhanced bioavailability in the conjunctival sac. Expert Opinion on Drug Delivery, 2019, 16, 657-666.	5.0	15
32	Ocular Surface Disease and Glaucoma Medications: A Clinical Approach. Eye and Contact Lens, 2019, 45, 11-18.	1.6	92
33	Topical preservative-free ophthalmic treatments: an unmet clinical need. Expert Opinion on Drug Delivery, 2020, 18, 1-18.	5.0	14
34	Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016. Acta Ophthalmologica, 2020, 98, e876-e881.	1.1	16
35	Comparison of preserved bimatoprost 0.01% with preservative-free tafluprost: A randomised, investigator-masked, 3-month crossover, multicentre trial, SPORT II. European Journal of Ophthalmology, 2021, , 112067212110065.	1.3	1
36	Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension. International Ophthalmology, 2021, 41, 3825-3835.	1.4	10

#	ARTICLE	IF	CITATIONS
37	When is preservative-free therapy of glaucoma needed and advisable?. Rossiiskii Oftal'mologicheskii Zhurnal, 2021, 14, 25-31.	0.4	0
38	Medication use and dry eye symptoms: A large, hypothesis-free, population-based study in the Netherlands. Ocular Surface, 2021, 22, 1-12.	4.4	11
39	Tear Film Osmolarity, Ocular Surface Disease and Glaucoma: A Review. Current Medicinal Chemistry, 2019, 26, 4241-4252.	2.4	11
40	Ocular Surface Disease in Glaucoma Patients Randomized to Benzalkonium Chloride-Containing Latanoprost and Preservative-Free Bimatoprost. Journal of Ocular Pharmacology and Therapeutics, 2021, 37, 556-564.	1.4	5
41	Preserved to preservative free prostaglandin analogues in primary open angle glaucoma. International Journal of Basic and Clinical Pharmacology, 2013, 2, 696.	0.1	0
42	Pharmacoeconomic aspects of glaucoma therapy with prostaglandin analogues in patients with signs of ocular surface disease. Ophthalmology Journal, 2015, 8, 99-103.	0.2	0
43	Zdravljenje glavkoma in suho oko. ZdravniÅški Vestnik, 2016, 85, .	0.1	0
44	Pharmacoeconomic analysis of the management of glaucoma with prostaglandin analogs. Zdravookhranenie Rossiiskoi Federatsii / Ministerstvo Zdravookhraneniia RSFSR, 2020, 64, 258-263.	0.4	0
45	Analysis of the effects of preservative-free tafluprost on the tear proteome. American Journal of Translational Research (discontinued), 2016, 8, 4025-4039.	0.0	7
46	A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications. Ophthalmology and Therapy, 2022, 11, 1681-1704.	2.3	4
47	Characteristics of tear meniscus using a spectral domain optical coherence tomography in medically controlled glaucoma. Indian Journal of Ophthalmology, 2023, 71, 2704-2710.	1.1	0
48	Impact of Clinician Subjectivity on the Assessment of Dry Eye Disease Prevalence in a UK Public Health Care Patient Population. Clinical Ophthalmology, 0, Volume 18, 743-753.	1.8	0